GleamWall
中文EN

TARS Tarsus Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1819790 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY86.3%
TTM net income YoY-765.3%
TTM EPS YoY-697.0%
Revenue 3-yr CAGR262.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-102.0%
Net margin-102.9%
FCF margin4.8%
EBITDA margin-101.7%

Returns

ROE-319.8%
ROA-135.0%
ROIC (approx.)-330.8%
Asset turnover1.31x

Leverage & solvency

Liabilities / assets79.4%
Debt / equity0.70x
Current ratio1.96x
Interest coverage-80.17x

Cash quality & payout

Operating cash flow / net income-0.07x
Accruals ratio-144.6%
Payout ratio—
Capex / revenue2.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$194.57M$173.91M$162.05M$151.67M$118.70M$102.66M$78.33M$66.41M
Cost of revenue$13.89M$12.11M$9.40M—$8.31M$6.24M$5.21M—
Gross profit$180.68M$161.80M$152.66M—$110.39M$96.42M$73.12M—
R&D expense$44.19M$31.01M$22.35M$18.04M$16.28M$15.59M$14.41M$16.87M
SG&A expense$168.02M$150.70M$136.43M$130.68M$108.63M$103.01M$85.00M$69.03M
Operating income-$662.09M-$19.91M-$6.12M-$7.98M-$14.53M-$22.18M-$26.28M-$24.42M
Interest expense$2.19M$2.16M$2.13M$2.21M$2.27M$2.24M$2.21M$2.31M
Income tax$4.64M$2.72M$2.35M$2.06M$0$0$0—
Net income-$668.33M-$18.55M-$6.97M-$8.37M-$12.59M-$20.34M-$25.12M-$23.11M
EBITDA-$661.29M-$19.11M-$5.92M-$7.77M-$14.33M-$21.98M-$26.06M-$24.23M
EPS (basic)-14.40-0.43-0.16—-0.30-0.48-0.64—
EPS (diluted)-14.40-0.43-0.16—-0.30-0.48-0.64—
Weighted avg. shares (diluted)46.42M43.39M42.96M—42.61M42.36M39.35M—
Balance sheet
Cash & equivalents$136.53M$204.59M$102.19M$183.64M$115.29M$99.21M$178.35M$97.38M
Short-term investments$173.08M$245.09M$286.54M$233.63M$289.11M$284.50M$232.13M$196.56M
Receivables$100.44M$96.03M$100.34M$85.06M$72.62M$58.33M$62.43M$46.76M
Inventory$5.16M$4.38M$4.57M$4.37M$3.84M$3.87M$2.71M$2.62M
Current assets$445.42M$561.99M$537.23M$522.78M$501.70M$474.43M$480.77M$356.70M
PP&E, net$20.72M$20.49M$17.67M$11.66M$5.75M$3.18M$2.79M$2.31M
Intangibles$16.64M$6.88M$7.13M$7.37M$7.61M$7.85M$8.09M$8.33M
Total assets$505.50M$611.14M$581.13M$562.16M$534.56M$494.99M$500.75M$376.99M
Current liabilities$227.11M$175.75M$143.51M$135.69M$117.05M$90.25M$86.31M$80.61M
Long-term debt$72.94M$72.76M$72.60M$72.44M$72.28M$72.13M$71.98M$71.84M
Total debt$72.94M$72.76M$72.60M$72.44M$72.28M$72.13M$71.98M$71.84M
Total liabilities$401.47M$264.41M$232.18M$218.73M$199.48M$162.38M$158.29M$152.46M
Shareholders' equity$104.03M$346.73M$348.95M$343.43M$335.08M$332.61M$342.46M$224.53M
Net debt-$63.59M-$131.83M-$29.59M-$111.20M-$43.01M-$27.08M-$106.37M-$25.54M
Shares outstanding49.30M43.27M43.02M42.55M42.45M42.21M42.00M38.35M
Cash flow statement
Operating cash flow-$6.00M$61.22M-$24.65M$19.33M$18.26M-$29.39M-$20.65M-$22.18M
Capital expenditure$1.21M$4.07M$5.82M$6.36M$1.91M$1.00M$590,000$72,000
Free cash flow-$7.21M$57.15M-$30.47M$12.97M$16.35M-$30.39M-$21.24M-$22.25M
Investing cash flow-$189.49M$37.88M-$58.56M$49.27M-$4.74M-$51.70M-$34.94M-$59.57M
Financing cash flow$127.81M$3.30M$1.20M$2.31M$2.56M$1.95M$136.56M$2.93M
Depreciation & amortization$800,000$800,000$197,000$202,000$200,000$200,000$220,000$192,000
Stock-based compensation$27.22M$13.29M$11.97M$14.31M$12.24M$8.23M$6.93M$7.40M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.